These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18375890

  • 1. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF.
    J Clin Oncol; 2008 Apr 01; 26(10):1611-8. PubMed ID: 18375890
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
    Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.
    J Clin Oncol; 2008 Apr 01; 26(10):1619-25. PubMed ID: 18375891
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep 01; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 01; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 01; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 6. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Sep 01; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 7. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 01; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 8. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
    Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM, Novotny PJ, Loprinzi CL.
    J Clin Oncol; 2011 Jan 01; 29(1):97-105. PubMed ID: 21098317
    [Abstract] [Full Text] [Related]

  • 9. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec 01; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 11. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May 20; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF.
    J Clin Oncol; 2008 May 10; 26(14):2342-9. PubMed ID: 18467726
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T.
    Jpn J Clin Oncol; 2010 Jun 10; 40(6):521-9. PubMed ID: 20508073
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 15. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Feb 15; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Feb 15; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 17. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 18. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 15; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 19. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
    Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J.
    J Clin Oncol; 2004 Apr 01; 22(7):1301-7. PubMed ID: 15051778
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A, RADAR Study Group.
    Curr Med Res Opin; 2012 Jan 01; 28(1):57-67. PubMed ID: 22070513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.